Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462488 · ClinicalTrials.gov registry record · Phase 2
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
A Phase 2 study, sponsored by Sesen Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00462488 is a Phase 2 study that has completed, run by Sesen Bio. The registered enrollment target is 46 participants.
The verdict
NCT00462488, a Phase 2 study, has completed, sponsored by Sesen Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous treatment with Bacille Calmette Guérin (BCG).
Interventions
- DRUG Vicinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00462488
The ClinicalTrials.gov registry entry for NCT00462488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sesen Bio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vicinium is the first listed.
NCT00462488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00462488 about?
NCT00462488 is a clinical study titled "Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ". The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous treatment with Bacille Calmette Guérin (BCG).
What is the current status of trial NCT00462488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2007-03. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00462488?
The interventions under investigation include: Vicinium (DRUG).
Who is sponsoring clinical trial NCT00462488?
This trial is sponsored by Sesen Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.